XML 66 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT - USD ($)
$ in Thousands
Total
Private Placement
Common Stock
Common Stock
Private Placement
Additional paid in capital
Additional paid in capital
Private Placement
Treasury stock
Accumulated deficit
Beginning balance, common shares (in shares) at Dec. 31, 2022     127,022,363          
Beginning balance at Dec. 31, 2022 $ (37,872)   $ 14   $ 272,528   $ (57,350) $ (253,064)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (26,214)             (26,214)
Equity-based compensation expense 3,805       3,805      
Issuance of Private Placement shares (in shares)       13,888,889        
Issuance of Private Placement shares   $ 7,081   $ 2   $ 7,079    
Issuance of shares for equity-based compensation awards, net (in shares)     911,861          
Issuance of shares for equity-based compensation awards, net (839)       (839)      
Issuance of shares for exercised convertible notes (in shares)     94          
Ending balance, common shares (in shares) at Mar. 31, 2023     141,823,207          
Ending balance at Mar. 31, 2023 $ (54,039)   $ 16   282,573   (57,350) (279,278)
Beginning balance, common shares (in shares) at Dec. 31, 2023 157,287,522   157,287,522          
Beginning balance at Dec. 31, 2023 $ (67,335)   $ 17   303,428   (57,350) (313,430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (125,147)             (125,147)
Equity-based compensation expense $ 5,157       5,157      
Exercise of options (in shares) 69,171   64,544          
Exercise of options $ 86       86      
Issuance of common shares as consideration for the acquisition of Pangiam (in shares)     61,838,072          
Issuance of common shares as consideration for the acquisition of Pangiam 207,776   $ 6   207,770      
Issuance of shares for equity-based compensation awards, net (in shares)     4,096,003          
Issuance of shares for equity-based compensation awards, net (2,762)       (2,762)      
Proceeds from exercise of 2023 warrants (in shares)     22,775,144          
Proceeds from exercise of 2023 warrants $ 90,707   $ 2   90,705      
Convertible debt conversion (in shares)     94          
Ending balance, common shares (in shares) at Mar. 31, 2024 246,061,379   246,061,379          
Ending balance at Mar. 31, 2024 $ 108,482   $ 25   $ 604,384   $ (57,350) $ (438,577)